Navigation Links
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Date:9/10/2007

ctions. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is expected to enter Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a Phase 1 clinical trial through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

About R7128

R7128 is being developed for the treatment of chronic hepatitis C. R7128 is a prodrug of PSI-6130, which demonstrated potency in preclinical studies. PSI-6130 is a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase, an enzyme that is necessary for hepatitis C viral replication. Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up to 3000 mg.

R7128 Phase 1 Study Overview

The Phase 1 clinical trial is a multiple center, observer-blinded, randomized and placebo-controlled study to investigate the pharmacokinetics, pharmacodynamics, safety, tolerability and food effect of R7128 in healthy volunteers and in patients chronically infected with HCV genotype 1. This Phase 1 study is comprised of two parts:

- Part 1 is a single ascending dose study of R7128 conducted in 46

healthy volunteers. The primary objective of Part 1 is to assess the

safety, tolerability and pharmacokinetics of R7128 following single

ascending doses under fasting conditions. The secondary objective of

P
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. ... Kinetics Corp.) is pleased to provide this review of ... growth in 2015. "Over this past year, ... and I am extremely proud to say that Monarch ... today than it has ever been," stated Eric ...
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between ... hearing health was forgotten. But Audicus , a ... hear better this new year. Hearing loss ... the aging population, though it is often unaddressed. Forty-eight ... four has a hearing aid, mainly due to price. ...
(Date:12/19/2014)... -- Decision Resources Group finds that the laparoscopic device market ... increase to a value of over $4.3 billion by ... the large direct energy device market. In particular, premium-priced ... to the advantages they offer and as new products ... Resources Group,s coverage of the U.S. laparoscopic device market: ...
Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Audicus Will Help People Resolve to Hear Better in 2015 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3
... undetectable HCV RNA levels following 4 weeks of, treatment with R7128 1500mg ... ... - Conference Call Scheduled for 4:00PM ET Today -, ... the preliminary results of a 4-week Phase 1,clinical trial to evaluate two ...
... Phase IIb study in the first half of 2008, ... ALSE ), announced today that it has,concluded enrollment ... acute,spinal cord injury (SCI). A total of 48 subjects ... and Canada. We expect to release periodic,updates of the ...
Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 2Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 3Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 4Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 5
(Date:12/22/2014)... December 22, 2014 The Bob ... ever, having invested more than $5 million in ... veterans and their families. , This includes $1.3 ... dozen nonprofits, helping with: veteran entrepreneurship; community impact; ... life-coaches for severely injured veterans. , “The needs ...
(Date:12/22/2014)... 2014 Give a loved one the ... of health and vitality. , For a limited time, ... anti-aging formulas in special Holiday Wellness gift packages at ... , Each bottle contains cutting-edge, proven nutritional support for ... as well as we age. , Joint ...
(Date:12/22/2014)... 22, 2014 Xarelto Lawsuit News ... of judges has granted a request to centralize pending ... District Court, Eastern District of Louisiana. The U.S. Judicial ... December 12 to transfer over 50 Xarelto cases–21 lawsuits ... the Louisiana court for consolidation under U.S. District Judge ...
(Date:12/22/2014)... St. Petersburg, FL (PRWEB) December 22, 2014 ... needed. Sublime Beauty® has a fast and easy solution that ... online gift cards can be purchased from from $25 up ... ®. "We offer 100% customer satisfaction and a wide array ... cards have no fees and no expiration dates. , ...
(Date:12/22/2014)... December 22, 2014 The ... professional development programs this month. Faculty have been ... on nurse educators fast-tracked for administrative leadership roles ... Development Program for Simulation Educators, featuring a curriculum ... of nursing education. , Twenty nurse educators ...
Breaking Medicine News(10 mins):Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3
... is marking its first National Women and Girls HIV/AIDS ... Fauci, MD, director of the National Institute of Allergy ... Health (NIH) // said in a press release, “This ... increasing impact of HIV/AIDS on women and girls in ...
... a zone in Torun, in northern Poland on the bank of ... Polish vets confirmed the presence of the H5N1 bird flu virus ... the German border but the vets did not confirm whether the ... put by Tadeusz Wijaszka, director of the national laboratory in Pulawy, ...
... passage, which results due to smoking is said to ... ,Called Chronic Obstructive Pulmonary Disease (COPD), ... and emphysema of the lungs. ,Unlike simple ... the mucous membrane and emphysema decomposes lung tissue. People ...
... breast cancer victims is denied by the NHS to victims ... private medical insurers have saved their day by pitching in. ... available this drug to almost 100 women, who have been ... the drug available in 30 such cases. ,It ...
... favor of the rise in Medicare bulk billing, which is ... Health Minister Tony Abbott released some alarming statistics that show ... ,According to Dr Kim Bulwinkel, from AMA Queensland, ... more patients, in order to make it a feasible option. ...
... that the risk of the H5N1 strain reaching Australia was ... the French parliamentary commission on the disease and put the ... ,It said that the avian flu was likely to ... chief vet Gardner Murray has rejected the world animal health ...
Cached Medicine News:
...
Lacrimal Cannula, Straight, Stepped DownSize: 19g x 1-1/2"....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: